| Symbol | CADL |
|---|---|
| Name | CANDEL THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 117 KENDRICK STREET,SUITE 450, NEEDHAM, Massachusetts, 02494, United States |
| Telephone | +1 617 916-5445 |
| Fax | — |
| — | |
| Website | https://www.candeltx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It is focused on helping patients fight cancer with oncolytic viral immunotherapies. Additional info from NASDAQ: |
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form ARS - Candel Therapeutics, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001841387-26-000005 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - Candel Therapeutics, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001841387-26-000004 <b>Size:</b> 3 MB
Read moreCandel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Read moreManning Paul B 🟢 acquired 4.6K shares (1 derivative) of Candel Therapeutics, Inc. (CADL) at $4.90 Transaction Date: Mar 31, 2026 | Filing ID: 000007
Read morePAPA JOSEPH C 🟢 acquired 2.8K shares (1 derivative) of Candel Therapeutics, Inc. (CADL) at $4.90 Transaction Date: Mar 31, 2026 | Filing ID: 000010
Read moreLoggia Nicoletta 🟢 acquired 779 shares (1 derivative) of Candel Therapeutics, Inc. (CADL) at $4.90 Transaction Date: Mar 31, 2026 | Filing ID: 000002
Read moreCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form SCHEDULE 13D/A - Candel Therapeutics, Inc. <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001494695-26-000005 <b>Size:</b> 14 KB
Read more(30% Negative) CANDEL THERAPEUTICS, INC. (CADL) Reports Q1 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Thera… | Phase1 | Malignant Glioma | Completed | 2010-10-01 | 2021-06-01 | ClinicalTrials.gov |
| NCT00638612 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) | Phase1 | Pancreatic Adenocarcinoma | Completed | 2008-08-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT00589875 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | Phase2 | Malignant Glioma | Completed | 2007-03-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Mal… | Phase1 | Malignant Glioma | Completed | 2005-11-01 | 2011-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| External Beam Radiation Therapy (EBRT) | RADIATION | Phase PHASE2 | Prostate Cancer Patients Treated by Radiotherapy | RECRUITING | NCT07332000 |
| aglatimagene besadenovec + valacyclovir | BIOLOGICAL | Phase PHASE2 | Prostate Cancer Patients Treated by Radiotherapy | RECRUITING | NCT07332000 |
| Laboratory Biomarker Analysis | OTHER | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Nivolumab | BIOLOGICAL | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Stereotactic biopsy | PROCEDURE | Phase PHASE1 | Malignant Glioma of Brain | ACTIVE_NOT_RECRUITING | NCT03152318 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Malignant Glioma of Brain | ACTIVE_NOT_RECRUITING | NCT03152318 |
| rQNestin | DRUG | Phase PHASE1 | Malignant Glioma of Brain | ACTIVE_NOT_RECRUITING | NCT03152318 |
| CAN-2409 + valacyclovir | BIOLOGICAL | Phase PHASE1 | Lung Cancer | COMPLETED | NCT03131037 |
| placebo | BIOLOGICAL | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02768363 |
| aglatimagene besadenovec | BIOLOGICAL | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02768363 |
| Surgery | PROCEDURE | Phase PHASE2 | Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT02446093 |
| Stereotactic body radiation therapy | RADIATION | Phase PHASE2 | Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT02446093 |
| Chemoradiation | RADIATION | Phase PHASE2 | Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT02446093 |
| Aglatimagene besadenovec | BIOLOGICAL | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04495153 |
| AdV-tk + valacyclovir | BIOLOGICAL | Phase PHASE1 | Malignant Pleural Effusion | COMPLETED | NCT01997190 |
| Placebo + valacyclovir | BIOLOGICAL | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT01436968 |
| Aglatimagene besadenovec + valacyclovir | BIOLOGICAL | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT01436968 |
| Radiation | RADIATION | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| valacyclovir | DRUG | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02768363 |
| AdV-tk | BIOLOGICAL | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Radiation therapy | RADIATION | Phase PHASE2 | Malignant Glioma | COMPLETED | NCT00589875 |
| Temozolomide | DRUG | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Valacyclovir | DRUG | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| CAN-2409 | BIOLOGICAL | Phase PHASE2 | Malignant Glioma | COMPLETED | NCT00589875 |